Dextrorphan: Difference between revisions
Line 15: | Line 15: | ||
Dextrorphan is structurally similar to [[dextromethorphan]], and has an affinity for the same receptors in the [[central nervous system]], although with a slight difference in selectivity. While dextromethorphan is a weak non-competitive [[NMDA receptor antagonist]], dextrorphan is a more potent antagonist[http://jpet.aspetjournals.org/cgi/content/full/309/2/515?ijkey=73c6efcf7713b02798c855b5ce4d50f1aa22d299&keytype2=tf_ipsecsha#ABS]. |
Dextrorphan is structurally similar to [[dextromethorphan]], and has an affinity for the same receptors in the [[central nervous system]], although with a slight difference in selectivity. While dextromethorphan is a weak non-competitive [[NMDA receptor antagonist]], dextrorphan is a more potent antagonist[http://jpet.aspetjournals.org/cgi/content/full/309/2/515?ijkey=73c6efcf7713b02798c855b5ce4d50f1aa22d299&keytype2=tf_ipsecsha#ABS]. |
||
It should be noted, however, that due to its potency as an NMDA receptor antagonist, as well as the fact that it is produced as a by-product of DM metabolization in the body, DX is thought to be largely responsible for the psychological side-effects that occur at high doses of DM. These side-effects can include alteration of consciousness, or "cognitive dissociation", which are |
It should be noted, however, that due to its potency as an NMDA receptor antagonist, as well as the fact that it is produced as a by-product of DM metabolization in the body, DX is thought to be largely responsible for the psychological side-effects that occur at high doses of DM. These side-effects can include alteration of consciousness, or "cognitive dissociation", which are characteristic of NMDA blockade and which have afforded DM its potential for abuse as a recreational drug. |
||
==See also== |
==See also== |
Revision as of 06:59, 21 September 2007
Dextrorphan (DX) is a pharmacologically active metabolite of dextromethorphan (DM, DXM).
File:Dextrorphan 2D.gif | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.004.323 |
Chemical and physical data | |
Formula | C17H23NO |
Molar mass | 257.371 g/mol g·mol−1 |
Chemistry
It is the result of O-demethylation of the prodrug by several enzymatic systems, although it is chiefly a product of the Cytochrome P450 IID6 (CYP2D6) pathway.
Pharmacology
Dextrorphan is structurally similar to dextromethorphan, and has an affinity for the same receptors in the central nervous system, although with a slight difference in selectivity. While dextromethorphan is a weak non-competitive NMDA receptor antagonist, dextrorphan is a more potent antagonist[1].
It should be noted, however, that due to its potency as an NMDA receptor antagonist, as well as the fact that it is produced as a by-product of DM metabolization in the body, DX is thought to be largely responsible for the psychological side-effects that occur at high doses of DM. These side-effects can include alteration of consciousness, or "cognitive dissociation", which are characteristic of NMDA blockade and which have afforded DM its potential for abuse as a recreational drug.
See also
- Dextromethorphan
- Ketamine (compound that acts most similarly to dextrorphan)
- Hallucinogen
- Psychedelic
- Racemethorphan
- Morphinans